April 03, 2025

New Option for IgA Nephropathy Management

The FDA has granted accelerated approval to Vanrafia (atrasentan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression.

Conexiant

April 02, 2025

HPV Testing Guidelines Updated for Head and Neck Carcinomas

New evidence expands recommendations for sinonasal squamous cell carcinoma and standardizes p16 immunohistochemistry interpretation.

Conexiant

April 02, 2025

FDA Approves Automated Latent TB Test

Revvity’s Auto-Pure 2400 platform for use with the T-SPOT.TB test to automate latent tuberculosis diagnostics was approved by the FDA.

Conexiant

April 01, 2025

Cracking the Bacterial Vaginosis Resistance Code

Investigators have identified distinct Gardnerella species with varying antibiotic resistance patterns, potentially guiding more effective treatment for recurrent bacterial vaginosis.

Conexiant

March 25, 2025

Microplastics: Chewing Gum May Release Particles Into Saliva

"Surprisingly, both synthetic and natural gums had similar amounts of microplastics released when we chewed them."

Conexiant

March 12, 2025

A Firm Pigmented Plaque on the Forearm of a Child: What's Your Diagnosis?

Rare pediatric Bednar tumor case highlights importance of histopathology and molecular testing in distinguishing uncommon dermatologic malignancies from benign pigmented lesions

Conexiant

March 06, 2025

An Estimated 31 Million Americans Borrowed for Medical Bills in 2024

A new West Health-Gallup Survey survey reveals insights into medical debt across all income levels and demographics in the United States.

Conexiant

March 05, 2025

FDA Monthly Round-Up: Key February Updates

February's FDA approvals feature advancements in cardiology, neurology, infectious diseases, and rare disorders, including the first trials for genetically modified pig kidney transplants and novel treatments for Parkinson’s disease and spinal muscular atrophy.

Conexiant

February 12, 2025

FDA & EMA: Submitted Trial Data Discrepancies

Sample size discrepancies were identified in 13 trials (65%), with 8 differing by more than 10%.

Conexiant